chr18-31593026-G-C
Variant summary
Our verdict is Pathogenic. The variant received 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000371.4(TTR):c.200G>C(p.Gly67Ala) variant causes a missense, splice region change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G67R) has been classified as Pathogenic.
Frequency
Consequence
NM_000371.4 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- amyloidosis, hereditary systemic 1Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- familial amyloid neuropathyInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- hereditary ATTR amyloidosisInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- heart conduction diseaseInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- ATTRV122I amyloidosisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 19 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| TTR | NM_000371.4 | c.200G>C | p.Gly67Ala | missense_variant, splice_region_variant | Exon 2 of 4 | ENST00000237014.8 | NP_000362.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| TTR | ENST00000237014.8 | c.200G>C | p.Gly67Ala | missense_variant, splice_region_variant | Exon 2 of 4 | 1 | NM_000371.4 | ENSP00000237014.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Amyloidosis, hereditary systemic 1 Pathogenic:3
This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 67 of the TTR protein (p.Gly67Ala). This variant also falls at the last nucleotide of exon 2, which is part of the consensus splice site for this exon. This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of transthyretin amyloidosis (PMID: 7951260, 10677864, 24053266, 34024775). It has also been observed to segregate with disease in related individuals. This variant is also known as p.Gly47Ala. ClinVar contains an entry for this variant (Variation ID: 13451). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). This variant disrupts the c.200G nucleotide in the TTR gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 12000196, 20209591). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Variant summary: The TTR c.200G>C (p.Gly67Ala) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this substitution (SNPs&GO not captured due to low reliability index). This variant is absent in 121408 control chromosomes but was reported in several patients suggesting causality. Moreover, in at least two families the variant was observed to co-segregate with the disease further supporting a pathogenic outcome. Different variants affecting the same codon are listed in HGMD/ClinVar with a casual classification indicating the variant to be located in a mutational hotspot which supports the clinical relevance of the Gly67 residue. In addition, the p.Gly67Ala is found worldwide and has a high prevalence in German familial amyloid polyneuropathy patients (Niemietz_PlosOne_2016). Taken together, this variant is classified as pathogenic.
not provided Pathogenic:1
Cardiovascular phenotype Pathogenic:1
The p.G67A pathogenic mutation (also known as c.200G>C), located in coding exon 2 of the TTR gene, results from a G to C substitution at nucleotide position 200. The amino acid change results in glycine to alanine at codon 67, an amino acid with similar properties. This mutation, which is also known as p.G47A, was first reported in two unrelated Italian families with transthyretin (TTR) amyloidosis; both families presented with peripheral neuropathy and cardiomyopathy (Ferlini A et al. Hum. Mutat., 1994;4:61-4; Ferlini A et al. Clin. Genet., 2000 Apr;57:284-90). In a large cohort of families with TTR amyloidosis, this mutation was identified in 7 individuals from 2 unrelated families; 4 of these individuals had a mixed cardiac and neurologic phenotype and 3 of these individuals only had neurologic phenotype (Rapezzi C et al. Eur. Heart J., 2013 Feb;34:520-8). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by BayesDel in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at